Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today
Aura AI Summary
Key Stats
- $109.25BMarket Cap
- HealthSector
- -15.21%3M Drawdown
- $103.99BEnterprise Value
- -Dividend Yield
- 38% Buy | 62% SellTrading Activity
- 102 daysTypical Hold Time
Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $109.25B, with an enterprise value of $103.99B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -15.21%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 102 days, indicating typical investor behavior on the platform.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Global drone service market to hit $256B by 2034 with 25.7% CAGR, led by Asia Pacific and infrastructure demand
The global drone service market, valued at $32.72 billion in 2025, is projected to grow to $256.09 billion by 2034, with a compound annual growth rate (CAGR) of 25.69%. Growth is driven by rising adoption in commercial, industrial, and defense sector...
SpaceX IPO may divert funds and focus from Tesla, raising concerns among investors.
The upcoming SpaceX IPO, scheduled for June, could shift investor attention and capital away from Tesla, potentially impacting Tesla's stock negatively. Experts suggest that Elon Musk might prioritize SpaceX, his 'new baby,' over Tesla, despite his h...
Yimutian requests Nasdaq hearing to avoid delisting over market value issues
Yimutian Inc., a Chinese agricultural digital service company, has formally requested a hearing with Nasdaq's Hering Panel after receiving a delisting notice due to not meeting minimum market value requirements. The hearing request halts any immediat...